文献速递免疫规划

百白破六联疫苗与MenACWY结合疫苗在幼儿中同时接种的III期研究

Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
PubMed 文献 · Vaccine · 2018-11-22

这项III期开放标签随机多中心研究纳入312名12月龄健康幼儿,随机接受DTaP-IPV-HB-PRP-T与MenACWY-TT同时接种、单用六联疫苗或单用MenACWY-TT疫苗。结果显示同时接种不影响两种疫苗的免疫应答,虽反应原性略高,但支持从12月龄起同时接种。

要点

  • 12月龄幼儿同时接种六联疫苗与MenACWY-TT疫苗的免疫应答不受影响。
  • 婴儿期接种MenC疫苗不影响后续使用MenACWY-TT疫苗进行加强免疫。
  • 同时接种后反应原性略高,但研究结果支持同时接种。

核心结论

  • 从12月龄起,DTaP-IPV-HB-PRP-T六联疫苗可与MenACWY-TT结合疫苗同时接种。

研究设计与样本

  • III期开放标签随机多中心研究,312名12月龄健康幼儿随机分为三组:同时接种组(n=104)、单用六联疫苗组(n=105)、单用MenACWY-TT组(n=103)。

主要发现

  • 无论初级系列是否同时接种MenC-TT结合疫苗,12月龄时各DTaP-IPV-HB-PRP-T疫苗抗原的抗体持久性无显著差异。
  • 加强免疫后,同时接种与分别接种相比,DTaP-IPV-HB-PRP-T和MenACWY-TT疫苗的免疫应答均未受影响。
  • 接种后1个月,同时或分别接种的两组疫苗均诱导高水平免疫应答。
  • 婴儿期接种MenC疫苗不妨碍后续使用MenACWY-TT疫苗进行加强免疫。
  • 同时接种后反应原性略高。

临床怎么用

  • 在12月龄幼儿中,可将DTaP-IPV-HB-PRP-T六联疫苗与MenACWY-TT结合疫苗安排同时接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Invasive meningococcal disease caused by Neisseria meningitidis is a life-threatening disease. Several countries now include meningococcal serogroup C (MenC) conjugate and, more recently, a meningococcal serogroup ACWY conjugate (MenACWY) vaccination in their national immunization schedules. DTaP-IPV-HB-PRP-T is a hexavalent vaccine that provides protection against six diseases. The phase III, open-label, randomised, multicentre study enrolled healthy toddlers who received the DTaP-IPV-HB-PRP-T vaccine (at 2, 3 and 4 months) with or without a MenC vaccine (at 2 and 4 months) in the primary series study. At 12 months of age, 312 toddlers were randomised to receive DTaP-IPV-HB-PRP-T co-administered with MenACWY-TT vaccine (Group A; n = 104); DTaP-IPV-HB-PRP-T vaccine alone (Group B; n = 105); or MenACWY-TT vaccine alone (Group C; n = 103). At 12 months of age, there were no notable differences in terms of antibody persistence for any DTaP-IPV-HB-PRP-T vaccine antigen, whether MenC-TT conjugate vaccine was co-administered or not during the primary series. Following booster vaccination, immune responses to DTaP-IPV-HB-PRP-T and MenACWY-TT vaccines were not affected by co-administration. One month after vaccination, the immune responses elicited by both vaccines were high, whether administered concomitantly or separately. The administration of MenC vaccine during infancy did not preclude the use of a MenACWY-TT vaccine for booster vaccination. Even though the reactogenicity after co-administration was somewhat higher, the results of this study support the concomitant administration of the DTaP-IPV-HB-PRP-T vaccine with a MenACWY-TT conjugate vaccine when given from 12 months of age. The clinical trial registration numbers are: clinicaltrial.gov: NCT01839175; EudraCT: 2012-005547-24.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vesikari T, Borrow R, Da Costa X, et al. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers. Vaccine. 2018. PMID: 30471953. doi:10.1016/j.vaccine.2018.10.100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。